Brief: Orion Expects Gross Profit To Increase, Mostly Driven By Growing Nubeqa Royalties

Orion Oyj

08/08/2024 11:43

Aug 8 (Reuters) - Orion Oyj  ORNBV.HE :
    * FIRST HALF OF 2024 WAS STRONG FOR OUR ANIMAL HEALTH
BUSINESS
DIVISION
    * OUTLOOK FOR 2024 UNCHANGED
    * CAPITAL EXPENDITURE IN 2024 IS EXPECTED TO BE AT A SIMILAR
LEVEL
AS IN 2023, WHEN CAPITAL EXPENDITURE WAS EUR 93
    * TOTAL CAPITAL EXPENDITURE IN 2024 IS EXPECTED TO BE AT A
SIMILAR
LEVEL AS IN 2023, WHEN CAPITAL EXPENDITURE WAS EUR 93 MILLION
    * SALES OF INDIVIDUAL PRODUCTS AND ALSO ORION'S SALES IN
INDIVIDUAL MARKETS MAY VARY
    * H1 INCREASE IN OPERATING PROFIT: STRONGEST IMPACT WAS ON
NUBEQA
ROYALTIES
    * NUBEQA CONTINUED TO PERFORM WELL AND WAS A CLEAR GROWTH
DRIVER
FOR ORION AND INNOVATIVE MEDICINES BUSINESS DIVISION
    * DEMAND FOR EASYHALER PRODUCTS REMAINED STRONG, WHICH
EXPLAINS
GROWTH OF PRODUCT PORTFOLIO AND, TO A LARGE EXTENT, OF BRANDED
PRODUCTS BUSINESS DIVISION
    * WE ARE PREPARING TO START CLINICAL PHASE II PROGRAM WITH
ODM-111
MOLECULE FOR TREATMENT OF ACUTE AND CHRONIC PAIN DURING 2024 OR
EARLY 2025
    * EXPECTS GROSS PROFIT TO INCREASE CLEARLY DRIVEN BY GROWING
NUBEQA ROYALTIES AND EUR 60 MILLION ITEM TO BE RELEASED FROM
BALANCE SHEET IN Q3 2024

Source text for Eikon:  ID:nGNE80syYy 
Further company coverage:  ORNBV.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))